SAB Biotherapeutics, Inc.
SABS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001833214
No open-market purchases or sales by SAB Biotherapeutics, Inc. insiders were filed in the last 90 days; 87 institutions reported holding it in 13F filings for Q2 2026, worth $266.8M in total; no superinvestor holds it.
Other share classesSABSW
Q4 2023 vs. Q3 2023
How the institutions holding SAB Biotherapeutics, Inc. changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Of which not filed for Q4 2023 | Q4 2023 | Change |
|---|---|---|---|---|
| Holders | 34 | 1 | 42 | +9 |
| Shares | 3.82M | 506.5K | 35.6M | +32.3M (+973.1%) |
| Value | $2.41M | $319.1K | $24.5M | +$22.4M (+1,069.5%) |
1 institution that held it in Q3 2023 haven't filed for Q4 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (14)
Institutions that held SAB Biotherapeutics, Inc. at the end of Q4 2023 but not at the end of Q3 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| BVF Inc | 9,178,282 | $6.31M | 0.16% |
| RTW Investments, LP | 9,178,282 | $6.31M | 0.10% |
| Marshall Wace, LLP | 4,585,282 | $3.16M | 0.01% |
| Sessa Capital IM, L.P. | 4,584,571 | $3.15M | 0.15% |
| Ra Capital Management, L.P. | 2,374,081 | $1.63M | 0.03% |
| Commodore Capital LP | 1,831,746 | $1.26M | 0.11% |
| Pathstone Holdings, LLC | 506,513 | $348.2K | 0.00% |
| Silver Oak Securities, Inc | 51,891 | $35.7K | 0.00% |
| Citadel Advisors LLC | 16,719 | $11.5K | 0.00% |
| Commonwealth Equity Services, LLC | 12,823 | $9.00K | 0.00% |
| Spectrum Wealth Counsel, LLC | 5,030 | $3.46K | 0.00% |
| LM Advisors LLC | 3,620 | $2.49K | 0.00% |
| UBS Group AG | 500 | $344 | 0.00% |
| Bank of America Corp | 54 | $38 | 0.00% |
Sold out (5)
Institutions that held SAB Biotherapeutics, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| HighTower Advisors, LLC | 73,470 | $46.0K |
| Brookstone Capital Management | 21,755 | $17.4K |
| LGL Partners, LLC | 23,000 | $14.5K |
| Strategic Financial Concepts, LLC | 15,027 | $9.47K |
| Harbour Investments, Inc. | 500 | $315 |
Not filed for Q4 2023 yet (1)
Institutions that held SAB Biotherapeutics, Inc. at the end of Q3 2023 and haven't filed a 13F for Q4 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Pathstone Family Office, LLC | 506,513 | $319.1K |